Company family
Viiv: medicine shortages
As of 2 Nov 2026, 4 Viiv products have a reported shortage across 2 countries, covering 3 medicines.
Products short4rank #328 of 464
Medicines3active ingredients
Countries2/16
New in 90 days2+2 vs market pace
Typical duration5 monthsmedian so far
Manufacturing0%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Lamivudine | 2 | 19 Oct 2026 | Not stated | 3/16 | |
| Dolutegravir | 1 | 11 Feb 2025 | Other | 1/16 | |
| Maraviroc | 1 | 20 Jan 2026 | Not stated | 1/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.